DSCO, Discovery Laboratories Inc.

HTDS, Hard to Treat Diseases

DrStockPick Watch List!

DrStockPick.com Watch List! for Tuesday September 15, 2009

My Picks for Tuesday September 15, 2009 are:

**************************************************************

DSCO, Discovery Laboratories Inc.

DSCO is a biotechnology company committed to the development and commercialization of novel Surfactant Replacement Therapies (SRTs™) with potential application across the respiratory disease continuum. Surfactant is produced naturally in the lungs and is essential for normal breathing throughout life.

DSCO’s product platform is based on a novel pulmonary surfactant technology intended to establish a completely new, therapeutic approach in the treatment of respiratory disease, with a targeted initial application in

Below are 12 companies with market caps below $200M which have pending new drug product decisions at the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced.

BioMedReports.com FDA Calendar

1.) Vion Pharma (VION.OB): Onrigin (laromustine) Injection (formerly known as Cloretazine or VNP40101M) NDA (filed with the FDA on 2/17/09) with priority review request as a single agent for remission induction treatment for patients age 60 and older with de novo poor-risk acute myeloid leukemia (AML). 4/17/09 is date for FDA to accept the filing and rule on priority review request - if granted the PDUFA would be 8/17/09 instead of 12/17/09 for standard 10-month review.

2.) Discovery Labs (DSCO): Surfaxin (lucinactant) NDA for prevention of respiratory distress syndrome (RDS) in premature infants. DSCO received its third approvable letter for Surfaxin last

Shares of Discovery Labs (DSCO) have been drifting lower in recent trading and now are at the $1.55 level, which is a nice entry point for a long position for speculative biotech investors. Since meeting with the FDA in mid-June, DSCO has trended lower on investor disappointment that the Company would delay its response to the most recent approvable ruling for Surfaxin until September. However, the Company still expects a Class I review (60 days), which could result in approval for Surfaxin by late November or early December without the need for additonal clinical trials. Summer is typically a slow time for biotech trading and provides a good time to accumulate shares ahead of a Fall catalyst.